Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL versus REVONTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL versus REVONTO.
CARISOPRODOL vs REVONTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing the effects of GABA to produce sedation and anxiolysis.
250-350 mg orally 3 times daily and at bedtime
4 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Clinical Note
moderateCarisoprodol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Carisoprodol is combined with Fluticasone propionate."
Clinical Note
moderateCarisoprodol + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Carisoprodol."
Clinical Note
moderateCarisoprodol + Ketoconazole
Terminal elimination half-life is approximately 18–20 hours in healthy adults, allowing once-daily dosing.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Renal excretion of unchanged drug accounts for <1% of the dose; fecal excretion via biliary elimination is the primary route (≈90%), with the remainder as metabolites.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Ketoconazole can be decreased when combined with Carisoprodol."